Plain-English translation of NCT06223711 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach to treat extensive-stage small-cell lung cancer (a fast-growing type of lung cancer) in people who have only a few tumors in their body. The study combines three treatments: (a drug that helps your immune system fight cancer), , and targeted radiation therapy. The goal is to see if this three-pronged approach works better than standard treatments alone.
Extensive-stage small-cell lung cancer is very aggressive and difficult to treat. For patients who have a limited number of tumors (called oligometastatic disease), there may be an opportunity to attack both the main tumor and the spread tumors more aggressively. This medication is designed to boost your immune system to recognize and destroy cancer cells, and combining it with radiation and might improve survival and quality of life.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive two more rounds of (given every three weeks) combined with radiation therapy to your main tumor, along with the immunotherapy medication. After that, you will receive targeted radiation therapy to any remaining tumors at other sites in your body, plus continuing doses of the immunotherapy medication given every four weeks as maintenance treatment. You will need to attend regular clinic visits for treatment delivery, blood tests, and imaging scans to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Germany